Drug Search Results
More Filters [+]

Vernakalant

Alternative Names: vernakalant, brinavess
Latest Update: 2024-05-22
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Potassium Channel Blocker,Sodium Channel Blocker

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Latvia | Lebanon | Lithuania | Luxembourg | Netherlands | New Zealand | Norway | Poland | Portugal | Romania | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | United Arab Emirates | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Advanz Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Vernakalant

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Atrial Fibrillation

Phase 3: Atrial Fibrillation|Atrial Flutter|Stroke|Heart Failure|Cardiac Arrhythmias|Ventricular Fibrillation

Phase 2: Heart Failure|Stroke|Atrial Fibrillation|Cardiac Arrhythmias|Atrial Flutter

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

REB20-2257

P3

Not yet recruiting

Atrial Fibrillation

2025-01-01

RAFF4 Trial

P4

Recruiting

Atrial Fibrillation

2023-09-30

SELECTCARFAP

P4

Completed

Atrial Fibrillation

2023-06-01

MK-6621-049

N/A

Completed

Atrial Fibrillation

2018-04-05

Recent News Events